ARIAD Announces Publication in Chemistry & Biology On Selective Small-Molecule Drug to Treat Osteoporosis.Business Editors & Health/Science Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2000 Selective inhibitor of intracellular signaling pathway in bone developed using structure-based drug design ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ARIA) today reported, in a research paper published in the March 2000 issue of Chemistry & Biology, the development of a new class of small-molecule drugs that inhibit the breakdown of bone resulting in osteoporosis. This is the first publication of a selective small-molecule drug that targets Src tyrosine kinase tyrosine kinase An enzyme intimately linked to signal transduction–ST, either as a receptor-type TK, which participates in transmembrane signaling, or as an intracellular TK, participating in ST to the nucleus; ↑ or ↓ TK activity is associated with , an intracellular signaling protein that is critical to the osteoporosis disease process, and blocks Src-mediated cellular activities and bone breakdown. Src has been extensively validated as a drug target for osteoporosis by gene deletion studies in animals and other genomics techniques. The paper by Violette et al is entitled "A Src SH2 selective binding compound inhibits osteoclast-mediated resorption resorption /re·sorp·tion/ (re-sorp´shun) 1. the lysis and assimilation of a substance, as of bone. 2. reabsorption. re·sorp·tion n. ." The Src inhibitors highlighted in this publication were developed by ARIAD scientists using structure-based drug design and are featured on the cover of the current issue of Chemistry & Biology. They are in a series of candidate compounds discovered by ARIAD for use in the treatment of osteoporosis. This experimental study demonstrates that it may be possible to treat osteoporosis with proprietary drugs that selectively block signaling pathways in osteoclasts Osteoclasts Bone cells that break down and remove bone tissue. Mentioned in: Bone Grafting, Osteoporosis without toxicity. "We recently acquired all of the drug candidates and related technologies resulting from our collaboration with Hoechst Marion Roussel on the development of Src tyrosine kinase inhibitors for osteoporosis. Our plan is to complete preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. on several classes of novel Src inhibitors as soon as possible and to move forward with a clinical candidate soon thereafter," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. ARIAD Pharmaceuticals (www.ariad.com) is engaged in the discovery and development of gene-targeted therapeutics based on signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. technology. ARIAD is developing gene therapy products, regulated by small-molecule drugs, for protein and cell therapy based on its proprietary gene regulation and gene activation technologies including the ARGENT ar·gent n. 1. Heraldry The metal silver, represented by the color white. 2. Archaic Silver or something resembling it. (TM) and RAPID(TM) systems. The Company also is developing orally administered small-molecule drugs to block intracellular signaling pathways that play a critical role in major diseases, such as osteoporosis and immune-related disorders. Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, which include, but are not limited to, risks and uncertainties regarding the Company's preclinical studies, the ability of the Company to conduct clinical trials of its products and the success of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on our collaborators and other factors under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 1998 filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion